Cargando…
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy
The calcipotriol/betamethasone dipropionate fixed-combination gel is widely used for topical treatment of psoriasis vulgaris. It has been hypothesized that calcipotriol counteracts glucocorticoid-induced skin atrophy which is associated with changes in the extracellular matrix (ECM). To elucidate th...
Autores principales: | Norsgaard, Hanne, Kurdykowski, Sandrine, Descargues, Pascal, Gonzalez, Tatiana, Marstrand, Troels, Dünstl, Georg, Røpke, Mads |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168021/ https://www.ncbi.nlm.nih.gov/pubmed/25027750 http://dx.doi.org/10.1007/s00403-014-1485-3 |
Ejemplares similares
-
Calcipotriol/Betamethasone Dipropionate Foam Inhibits Th17 Cytokine Secretion and Improves Epidermal Barrier Markers in a Human Th17 Skin Inflammation Model
por: Lovato, Paola, et al.
Publicado: (2021) -
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008) -
Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
por: Rogalski, Christina
Publicado: (2015) -
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019) -
Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial
por: Wen, Ze-Huai, et al.
Publicado: (2014)